Beigene Ltd.’s selective inhibitor, Brukinsa (zanubrutinib), made up for a 2019 miss in a head-to-head study against Johnson & Johnson and Abbvie Inc.’s Imbruvica (ibrutinib) with positive new data from a phase III trial.
HONG KONG – Shionogi & Co. Ltd. has inked a multitarget drug discovery collaboration for Inveniai LLC’s artificial intelligence and machine learning platform Alphameld.
To honor its part for phase one of the U.S.-China trade deal, China has revised its patent law to establish a drug patent linkage system and provide compensation for lost patent terms.
Using advanced intravital microscopy to visualize immune cell movement within the tissues, investigators at the Peter Doherty Institute for Infection and Immunity, Melbourne have discovered that noradrenaline causes a dramatic paralysis of immune cell movement.
Regulatory snapshots, including drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations in Asia-Pacific, including: Ampio, Biontech, Camurus, CSL Behring, Eagle, Galmed, Hutchmed, Moderna, Pfizer, RDIF, Takeda.
Biopharma happenings in Asia-Pacific, such as deals and partnerships, grants, preclinical data and other news in brief, including: Aft, Asahi Kasei, Canbridge, Centivax, Cipla, Cocrystal, Daiichi Sankyo, Dr. Reddy’s, Emcure, Fera, Generex, Gilead Sciences, Guardant Health, Hetero Labs, Hikma, Inveniai, Logicbio, Merck, Mirum, Moderna, New Life, Nicox, Ose Immunotherapeutics, Revive, Ridgeback, Shionogi, Sirnaomics, Soligenix, Sonnet Bio, Sun Pharmaceutical Industries, University of Dundee, VBI Vaccines, Walvax.
HONG KONG – Lutris Pharma Ltd., a company taking on the dermal toxicity common to cancer therapy with EGFR inhibitors, has begun testing its lead product, the B-Raf inhibitor LUT-014, in a phase II trial targeting reduction of acne-like lesions associated with the class. Partial results are expected by the end of 2021.
Regulatory snapshots, including drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations in Asia-Pacific, including: Algernon, Biogen, Chugai, Cstone, Eisai, Gilead Sciences, Glenmark, Hua Medicine, Johnson & Johnson, Medicago, Merck, Shanghai Henlius, Transcenta.
RSS
